17. Multiple system atrophy Clinical trials / Disease details

Clinical trials : 118 / Drugs : 163 - (DrugBank : 49) / Drug target genes : 61 - Drug target pathways : 112

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01136213 (ClinicalTrials.gov)	April 2010	26/5/2010	Investigation of the Serotoninergic System in Multiple System Atrophy: a Positron Emission Tomography (PET) Study	Morphological and Functional Investigation of the Serotoninergic System in Multiple System Atrophy: a 18F-MPPF PET Study	Multiple System Atrophy	Radiation: PET (Positron Emission Tomography) Study;Other: Brain MRI (magnetic resonance imaging);Drug: Fluoxétine / Placebo	University Hospital, Bordeaux	NULL	Completed	30 Years	80 Years	All	53	N/A	France
2	NCT01146548 (ClinicalTrials.gov)	May 2008	16/6/2010	Fluoxetine in Multiple System Atrophy Patients	Assessment of Fluoxetine's Effect in Patients With Multiple System Atrophy : a Double Blind Placebo-controlled Randomized Trial	Multiple System Atrophy	Drug: FLUOXETINE	University Hospital, Toulouse	Clinical Research Center, Toulouse	Completed	30 Years	80 Years	Both	87	Phase 2	France
3	EUCTR2007-004922-26-FR (EUCTR)	12/02/2008	31/01/2008	Evaluation de l’effet de la fluoxétine chez le patient atteint d’atrophie multi-systématisée : Etude randomisée en double-insu versus placebo. - Etude MSA-fluoxétine	Evaluation de l’effet de la fluoxétine chez le patient atteint d’atrophie multi-systématisée : Etude randomisée en double-insu versus placebo. - Etude MSA-fluoxétine	atrophie multisystématisée MedDRA version: 9.1;Level: LLT;Classification code 10064060;Term: Multiple system atrophy	Trade Name: PROZAC	CHU Toulouse	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			France